Immunization

A fatal pediatric measles case in Los Angeles highlights the urgent need for MMR vaccination to protect vulnerable children from severe complications.

The rationale for vaccine-related policy changes is lacking.

Experts forecast a potential resurgence of measles and other vaccine-preventable diseases in the U.S. due to declining vaccination rates.

According to phase 3 trial results, Pfizer-BioNTech’s LP.8.1-adapted COVID-19 vaccine demonstrated significant immune responses in older adults and individuals at high risk for severe COVID-19.

Florida's Surgeon General's plan to eliminate school vaccine mandates raises concerns about measles outbreaks and declining vaccination rates.

The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles-mumps-rubella vaccine.

Crystal Hodge, PharmD, BCIDP, BCPS, emphasizes that declining vaccination rates below the 95% herd immunity threshold have fueled recent measles outbreaks, underscoring the urgent need for pharmacist-led vaccination advocacy.

E. Camille Vaughan, MD, MS, highlights how pharmacists can build patient trust, encourage vaccination, and use simple strategies to spark conversations with hesitant individuals.

Research reveals how aging impacts flu severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.

E. Camille Vaughan, MD, MS, addresses how state-level differences and potential new prescription requirements could impact patient access to COVID-19 vaccines this fall.

New findings suggest high-dose influenza vaccines offer better protection against the flu and reduce cardiac complications in older adults.

A single dose of an RSV vaccine significantly reduces hospitalization risk for older adults, offering protection for 2 seasons against severe infections.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

Greater effectiveness was seen in children 1 year and older.

FluMist Home, the first at-home nasal spray flu vaccine, is now available for direct delivery to patients in 34 US states.

The FDA's approvals follow new COVID-19 guidance announced by the commissioner of the agency in May 2025, focusing future approvals on older adults.

The FDA suspended the biologics license for Ixchiq, the first approved chikungunya vaccine, after reports of serious adverse events and fatalities.

A novel shingles vaccine candidate demonstrated positive top-line results of antibody and CD4⁺ T-cell vaccine responses.

Patients in an outpatient oncology unit expressed willingness to receive a pneumococcal or influenza vaccine from a pharmacist if offered.

Alyssa Modic, PharmD, emphasizes the importance of evidence-based advocacy and continuous education as vaccine recommendations evolve.

Samantha Picking, PharmD, senior director of immunizations at Walgreens, shares how pharmacy teams are addressing vaccine misinformation, managing coadministration, and supporting test-to-treat services during a complex respiratory season.

RSVpreF was well tolerated in nonpregnant and pregnant individuals aged 18 years and older.

The AAP unveiled its 2025 immunization schedule, challenging CDC guidelines and emphasizing evidence-based vaccine recommendations for children's health.

Samantha Picking, PharmD, senior director of immunizations at Walgreens, discusses staffing strategies, digital tools, and operational improvements designed to streamline flu vaccination services during the upcoming respiratory season.

Case highlights the importance of careful cocumentation.